Om kinome profiling of cells treated with distinct concentrations of MK-2206 and for different time intervals. 1_30: treatment of 30 min with 1 M of MK-2206, etc. Abbreviations ALL: Acute lymphoblastic leukemia; DE: Differentially expressed; FDR: False discovery price; adjP: FDR adjusted P-value; IC50: Half maximal inhibitory concentration; IPA: Ingenuity pathways analysis; logFC: Log fold adjust; MSC: Mesenchymal stem cell; Ser/Thr: Serine/threonine. Competing interests Riet Hilhorst and Monique Mommersteeg are PamGene International B.V. staff. The other authors declare that they have no conflict of interests. Authors’ contributions MLK performed all bioinformatics analyses and wrote the manuscript. RH and MM performed kinome profiling experiments. BEWMA and MLK performed inhibition studies. EPB and MS had been involved in collection of cell line data. MLK, AMC, PCWH, RH, and HB designed the study. All authors read and authorized the final version from the manuscript. Acknowledgments The authors would like to thank N. Duinkerken for the NALM-6 cell line. This study was funded by EuroBoNeT (LSHC-CT-2006-018814), the Dutch Cancer Society (KWF, 2008060), the Netherlands Organization for Overall health Investigation and Improvement (9200399). Author information 1 Division of Pathology, Leiden University Healthcare Center, Albinusdreef two, 2300RC Leiden, The Netherlands. 2Current affiliation: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA. 3Current affiliation: Division of Biostatistics, Harvard School of Public Well being, Boston, MA, USA. 4PamGene International BV, `s-Hertogenbosch, The Netherlands. 5Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands. MMP-13 Inhibitor Molecular Weight 6Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy. 7Institute of Pathology, Paderborn/H ter, Germany. Received: 24 April 2013 Accepted: 14 January 2014 Published: 21 January 2014 References 1. Raymond AK, Ayala AG, Knuutila S: Conventional osteosarcoma. In World Well being Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Edited by Fletcher CDM, Unni KK, Mertens F. Lyon: IARC Press; 2002:26470.2.three.4.five.six. 7.eight. 9.ten.11. G, Longhi A, Versari M, PARP Activator MedChemExpress Mercuri M, Briccoli A, Picci P: Prognostic elements for osteosarcoma from the extremity treated with neoadjuvant chemotherapy – 15-year knowledge in 789 sufferers treated at a single institution. Cancer 2006, 106:1154161. Buddingh EP, Anninga JK, Versteegh MI, Taminiau AH, Egeler RM, van Rijswijk CS, Hogendoorn PCW, Lankester AC, Gelderblom H: Prognostic things in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer 2010, 54:21621. Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR: A meta-analysis of osteosarcoma outcomes within the modern healthcare era. Sarcoma 2012, 2012:704872. Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AHM, Hogendoorn PCW, Egeler RM: Chemotherapeutic adjuvant remedy for osteosarcoma: exactly where do we stand Eur J Cancer 2011, 47:2431445. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M: Emerging drugs for high-grade osteosarcoma. Professional Opin Emerg Drugs 2010, 15:61534. Cleton-Jansen AM, Buerger H, Hogendoom PCW: Central high-grade osteosarcoma of bone: diagnostic and genetic considerations. Curr Diagn Pathol 2005, 11:39099. Szuhai K, Cleton-Jansen AM, Hogendoorn Pc, Bovee JV: Molecular pathology and its diagnostic us.

By mPEGS 1